Table 2:

Multivariable Regression Analysis for Independent Predictors of CPM in AllT4^a Cohort

Independent Predictors	AOR	95% Confidence Interval	P-Valueb
Age, year: [≥65]	Reference
[50–64]	1.97	1.70–2.28	<0.001
[18–49]	3.14	2.67–3.69	<0.001
Race: White	Reference
Black	0.48	0.42–0.55	<0.001
Other/unknown	0.44	0.35–0.57	<0.001
Ethnicity H/L vs. non-H/L	0.54	0.44–0.65	<0.001
Education: % of No HSDc: [≥21]	Reference
[13–20.9]	1.06	0.93–1.21	0.238
[7–12.9]	1.17	1.03–1.32	0.002
[< 7]	1.24	1.09–1.42	<0.001
Insurance status: None	Reference
Medicare	1.21	0.95–1.54	0.122
Medicaid	1.09	0.86–1.36	0.485
Other Government	1.60	1.04–2.47	0.034
Private	1.57	1.28–1.94	<0.001
Facility type: CCP	Reference
Academic/research	0.97	0.84–1.13	0.724
CCCP	1.24	1.08–1.42	0.002
INCP	1.37	1.16–1.63	<0.001
Clinical AJCC T4abc	Reference
Clinical AJCC T4d	1.35	1.23–1.48	<0.001
Clinical AJCC NOS	1.00	0.90–1.11	0.939
Tumor size ≤20 vs >20 mm	1.23	1.09–1.38	0.001
Clinical AJCC N Status: 0	Reference
1	1.04	0.94–1.14	0.502
2	0.95	0.84–1.08	0.413
3	0.93	0.80–1.07	0.306
ER Positive vs negative	1.05	0.94–1.18	0.409
PR Positive vs negative	0.91	0.81–1.02	0.111
HER2 Positive vs negative	1.09	0.96–1.25	0.190
Chemotherapy: None
Neoadjuvant	3.79	2.79–5.13	<0.001
Adjuvant	2.51	1.83–3.43	<0.001
PMRT: None	Reference
Yes	1.17	1.07–1.29	0.001
IBR vs no IBR	2.24	2.01–2.50	<0.001

^aAllT4 = Tabc+T4+NOS (not otherwise specified)

^bAdjusted for age, race, ethnicity, education, payer and facility type, tumor size, T4d and nodal status, chemotherapy, radiotherapy, and IBR

^cNo HSD: Percentage of no high school degree by zip codes

CPM, contralateral prophylactic mastectomy; AOR, adjusted odds ratio; H/L Hispanic/Latino; HSD, high-school degree; CCP, community cancer program; CCCP, comprehensive community cancer program; INCP, integrated network cancer program, AJCC, American Joint Committee on Cancer, ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; PMRT Post-mastectomy radiotherapy; IBR Immediate b